戻る
Caribou Biosciences Inc (CRBU)価格
CRBU 株価推移チャート
CRBU 収入
Caribou Biosciences Inc
$1.52
-4.4%
$-0.07
終値： Feb 12, 16:00:00 GMT-5
$1.52
0%
$0
プレマーケット： Feb 13, 04:49:08 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-12
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
CRBUの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Caribou Biosciences Inc CRBUの前四半期の収益はどうでしたか？
Caribou Biosciences Incの収益見積もりはいくらですか？
Caribou Biosciences Incの収益品質スコアはどれくらいですか？
Caribou Biosciences Incはいつ収益を報告しますか？
Caribou Biosciences Incの予想収益はいくらですか？
Caribou Biosciences Incは収益予想を上回りましたか？
主要データ
前終値
$1.59
始値
$1.57
当日レンジ
$1.47 - $1.58
52週レンジ
$0.66 - $3.53
取引高
795.4K
平均取引高
1.0M
1株当たり利益(TTM)
-1.70
配当利回り
--
時価総額
$142.0M
CRBUとは何ですか？
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 147 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.